Immunotherapy based on the adoptive transfer of naturally occurring or gene-engineered T
cells can mediate tumour regression in patients with metastatic cancer. Here, we discuss …

Chimeric antigen receptor (CAR) gene-engineered T cell therapy holds the potential to
make a meaningful difference in the lives of patients with terminal cancers. For decades …

Combinations of BRAF inhibitors and MEK inhibitors (BRAFi+ MEKi) are FDA-approved to
treat BRAF V600E/K-mutant melanoma. Efficacy of BRAFi+ MEKi associates with cancer cell …

Activated T cells differentiate into functional subsets with distinct metabolic programs.
Glutaminase (GLS) converts glutamine to glutamate to support the tricarboxylic acid cycle …

Understanding resistance to antibody to programmed cell death protein 1 (PD-1; anti-PD-1)
is crucial for the development of reversal strategies. In anti-PD-1-resistant models …

Therapeutic harnessing of adaptive immunity via checkpoint inhibition has transformed the
treatment of many cancers. Despite unprecedented long-term responses, most patients do …

Regenerative stem cell–like memory (TSCM) CD8+ T cells persist longer and produce
stronger effector functions. We found that MEK1/2 inhibition (MEKi) induces TSCM that have …

T cells undergo metabolic rewiring to meet their bioenergetic, biosynthetic and redox
demands following antigen stimulation. To fulfil these needs, effector T cells must adapt to …

Treatment of solid tumors with T cell therapy has yielded limited therapeutic benefits to date.
Although T cell therapy in combination with proinflammatory cytokines or immune …

Vitiligo is an autoimmune disease of the skin mediated by CD8+ T cells that kill melanocytes
and create white spots. Skin lesions in vitiligo frequently return after discontinuing …